Collectively, we have proposed a multifunctional DNA hydrogel for synergistic therapy of HER2-positive breast cancer with targeted codelivery therapeutic nucleic acid (HER2 aptamer) and chemodrugs (DOX). Here, ERBB2 is linked to breast cancer.